An observational study in Neurocognitive Disorders, sponsored by Centre Hospitalier Universitaire de Nice. Recruiting at 1 site in France. Open to participants aged 50 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-03-19.
Sponsored by Centre Hospitalier Universitaire de Nice · Observational
Among 27 studies in Alzheimer Disease by Centre Hospitalier Universitaire de Nice — 3 open to participants now, 4 under way, none of them phase 3. Alzheimer Disease · Centre Hospitalier Universitaire de Nice.
Among the 27 studies in Alzheimer Disease by Centre Hospitalier Universitaire de Nice, this one is one of 2 that started in 2023, is one of 5 observational ones, and was the 24th registered.
3,965 studies on the registry are indexed under Alzheimer Disease; 926 are open to participants now.
This study's planned enrollment of 100 is below the median of 200 across 814 observational studies indexed under Alzheimer Disease.
Browse Alzheimer Disease studies →3 of the 27 studies in Alzheimer Disease by Centre Hospitalier Universitaire de Nice are open now, in 1 country. Each count lists the studies.
Of the 641 Alzheimer Disease studies recruiting now, 283 (44%) set no upper age limit and 54 (8%) stop at 75 or younger; 34 take children under 18; 283 take healthy volunteers.
This study: 50 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →27 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 2 started in 2023.
Median enrollment 45 across the 22 interventional studies, 94 across the 5 observational. Of the 17 that completed or were terminated, 0 (0%) have results posted.
Centre Hospitalier Universitaire de Nice is the lead sponsor of 723 studies on the registry; 176 are open to participants now.
1 of the studies in Alzheimer Disease by Centre Hospitalier Universitaire de Nice that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05943834Centre Hospitalier Universitaire de NiceEarly Detection of Alzheimer's Disease and Affective Disorders by Automated Voice and Speech Analysis (PLATA) | 2027-10-10 |
Among the 27 studies in Alzheimer Disease by Centre Hospitalier Universitaire de Nice, from their registry updates:
PLATA aims to develop an algorithm to identify vocal biomarkers of Alzheimer's dementia.
Using data collected as part of routine care, speech patterns will be compared to known biomarkers of Alzheimer's disease, such as amyloid 1-42 and p-Tau in CSF (cerebrospinal fluid).
If biomarkers of speech can be identified in Alzheimer's disease, it is possible that patients and research participants will no longer need to undergo need to undergo the intensive and invasive baseline biomarker methods currently used, such as lumbar punctures and PET scans.
3,965 studies on the registry are indexed under Alzheimer Disease; 926 are open to participants now.
This study's planned enrollment of 100 is below the median of 200 across 814 observational studies indexed under Alzheimer Disease.
Browse Alzheimer Disease studies →Centre Hospitalier Universitaire de Nice is the lead sponsor of 723 studies on the registry; 176 are open to participants now.
Compared within Alzheimer Disease, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neurocognitive Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Participants will be recruited through the Memory Clinic at the Geriatric Hospital in Nice (Centre de Mémoire de Ressources et de Recherche, CHU de Nice, Institut Claude Pompidou 10 rue Molière, 06 100 NICE) with a minor or major neurocognitive disorder whose etiology is either:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Every patient will receive one semi-automated phone call, during the call a series of cognitive tasks will be performed. Each task will be recorded in a secondary audio stream which records the participant responses to allow for deep speech analysis of performance on these tasks
Other: Series of cognitive tasks during a semi-automated call
Tasks: * Verbal learning recall (immediate) or Story Recall task (immediate) * Narrative Storytelling /free speech * Verbal fluency task * Verbal learning recall (delayed) or Story Recall task (delayed)
Build and validate speech-based machine learning models for relevant Phenotype detection through access to phenotyped patients from reference memory center.
Speech biomarker algorithm(s)
Time frame: 20 minutes
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2023 (actual). Primary completion is estimated for Oct 2027, 50 months after the start.
Of 364 non-industry observational studies under Alzheimer Disease, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 203. This study's planned 50 months is below that.
Counting every sponsor, half of 405 studies reached it within 67 months; a quarter within 35 and three quarters within 171.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Hospitalier Universitaire de Nice →